Record-Breaking Round: Biorce Secures $52.5M to Slash Clinical Trial Timelines with AI

Biorce, a health-AI pioneer based in Barcelona, has announced the successful closing of a $52.5 million Series A funding round. The investment marks the largest Series A ever recorded in the Iberian healthtech and AI ecosystem, signaling a massive shift in how the pharmaceutical industry intends to manage the $120 billion annual cost of clinical trials.

The round was led by DST Global Partners, with significant participation from existing investors Norrsken VC and YZR Capital, who both doubled down on their initial commitments. The capital will be used to fuel Biorce's "Aika" platform and spearhead a major expansion into the United States.

1. The "Aika" Engine: 90 Seconds to a Protocol
At the heart of the funding is Aika, Biorce’s proprietary AI-native platform. While traditional clinical trial design is a grueling, manual process that can take months, Aika is designed to automate the heavy lifting of trial architecture.

Regulator-Ready Protocols: The system can generate complex, "regulator-ready" trial protocols in just 90 seconds with a reported 86% accuracy rate.

Massive Data Foundation: Aika is trained on a proprietary dataset of over 1 million past clinical trials, allowing it to identify potential design flaws and "amendment risks" before a study even begins.

50% Faster Setup: Biorce claims the platform reduces the time spent on trial preparation and paperwork by half, potentially bringing life-saving drugs to market years ahead of schedule.

2. The Austin Expansion: Chasing the US Biotech Market
With $52.5 million in fresh capital, Biorce is pivoting toward a "US-first" commercial strategy.

Texas R&D Hub: The company is set to launch a new development and R&D hub in Austin, Texas. This location will serve as the bridge to the American biotech and pharmaceutical ecosystem, placing Biorce’s engineers in the same time zone as major US clinical research organizations (CROs).

Workforce Growth: Biorce plans to quadruple its workforce, expanding from 60 to 250 employees by the end of 2026. New hires will be split evenly between its Barcelona headquarters and the new Austin facility.

Profitability Path: Having generated over €10 million in revenue last year, CEO Pedro Coelho indicated that the company is on track for net profitability by late 2026, a rarity for an AI firm at this growth stage.

3. A "Who’s Who" of AI and Tech Investors
The round attracted a high-profile lineup of angel investors, suggesting that Biorce is viewed as a foundational infrastructure player rather than a niche medical tool:

Nik Storonsky: CEO of Revolut.

Arthur Mensch: Co-founder and CEO of Mistral AI.

Paulo Rosado: Founder of OutSystems.

Albert Nieto: Founder of Seedtag.

These tech titans are betting that Biorce can solve the "Protocol Amendment" crisis—a single error in trial design that currently costs pharma companies an average of $1 million per change and halts patient recruitment for weeks.

4. Eliminating the "Human Error" Bottleneck
Clinical trials currently take an average of 11 years and cost over $6 billion to bring a single drug to market. Biorce’s mission is to move the industry toward a "one-click clinical trial" model.

Therapy-Agnostic Approach: Unlike AI tools built for specific diseases, Aika is "disease-agnostic," meaning it is currently being used for everything from oncology and neurology to rare disease research.

Reducing Patient Attrition: Beyond design, the new funding will support modules for contract management and operational execution, helping trial sites stay organized and reducing the "burnout" that often leads to trial failures.

CEO Insight: "Clinical trial delays don't just cost money; they cost lives," said Pedro Coelho, CEO of Biorce. "This round isn't just a validation of our tech—it’s a signal that the industry is finally ready to move away from the slow, manual methodologies of the past century."